NDASUBCUTANEOUSINJECTABLE
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
BYETTA (exenatide synthetic) by AstraZeneca is incretins, such as glucagon-like peptide-1 (glp-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. Approved for type 2 diabetes mellitus. First approved in 2009.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYETTA (exenatide synthetic) is a GLP-1 receptor agonist injectable for type 2 diabetes that enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. It works by binding and activating human GLP-1 receptors to increase insulin synthesis and secretion through cyclic AMP signaling pathways. The drug improves glycemic control by reducing both fasting and postprandial glucose concentrations.
$0.021BPart D
LOE ApproachingProduct approaching LOE with modest Part D spending of $21M (14K claims in 2023); commercial teams face declining opportunity as exclusivity erodes.
Mechanism of Action
Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the…
Indications (1)
Clinical Trials (4)
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
Started Feb 2011
2,948 enrolled
Type 2 Diabetes
Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
Started Jan 2010
15 enrolled
Hyperlipidemia
Intravenous Exenatide (Byetta) During Surgery
Started Mar 2009
104 enrolled
EuglycemiaHypoglycemiaHyperglycemia
Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients
Started Feb 2008
41 enrolled
Type 2 Diabetes Mellitus
Worked on BYETTA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.